In addition to enhancing baseline NF-κB activation, MYD88L265P also promotes malignant B-cell growth by promoting autocrine and paracrine signaling of cytokines through activation of the JAK-STAT pathway in DLBCL cells. Here, NFKB1 is linked to diffuse large B-cell lymphoma.